欢迎来到凯学生物科技(上海)有限公司网站!

热门关键词:进口ELISA试剂盒,人ELISA试剂盒,大鼠elisa试剂盒价格,小鼠elisa试剂盒价格,猪elisa试剂盒,鸡elisa试剂盒,兔elisa试剂盒,鱼elsa试剂盒,其他种属elisa试剂盒,豚鼠elisa试剂盒,仓鼠elisa试剂盒,裸鼠ELISA试剂盒,进口试剂,血清,动物血清,人血清,胎牛血清,氨基酸试剂,培养基,显色培养基,大肠杆菌O157培养基,细菌总数培养基,金黄色葡萄球菌检验培养基,沙门氏菌/贺氏菌检验培养基, 弧菌检验培养基,其他培养基,酵母 霉菌 青霉 曲霉培养基, 李斯特氏菌检验培养基,抗体,二抗,一抗,生物试剂,酶生物试剂,蛋白质试剂,抗生素试剂,植物激素及核酸试剂,碳水化合物试剂,色素试剂,维生素试剂,表面活性剂,缓冲试剂,其他生化试剂,标准品对照品类,对照品,对照药材,标准品,标准试剂,Spectrum试剂,美国药典级试剂等

新闻中心您现在的位置:首页 > 新闻中心 > Blood-based immunoassay for the diagnosis of Alzheimer’s disease

Blood-based immunoassay for the diagnosis of Alzheimer’s disease

发布时间:2013-01-10   点击次数:1770次

IBL International and the LVR-clinics at the Essen University Hospital of the University Duisburg-Essen will cooperate on the development of a blood-based immunoassay for the diagnosis of Alzheimer’s disease

 

Hamburg, Germany - 17th September, 2012 . IBL International signed a world-wide, exclusive licence agreement with the University of Duisburg-Essen to develop and commercialize a blood-based immunoassay for the early diagnosis of Alzheimer’s disease. Currently, the clinical diagnosis is supported by the measurement of biomarkers in cerebrospinal fluid using in-vitro diagnostic assays. In order to contribute to widespread routine application, reliable blood-based biomarkers are required as well as suitable quantitative analytical assays.

 

The assay will be developed within the Neuroallianz Consortium, of which IBL International and the University of Duisburg-Essen are partners. The Neuroallianz Consortium is a research cooperation in conjunction with the Pharmaceuticals Initiative in Germany. The Consortium is supported by the German government and received EUR 40 million since it became active in 2009.

 

Both parties are very pleased with the new license agreement. Studies from the University of Duisburg-Essen show promising evidence that the ratio of the novel amyloid-peptide variants as measured in blood meet the requirements of a blood-based biomarker. Professor Jens Wiltfang, Head of the Department of Psychiatry and Psychotherapy of the LVR-clinics at the University of Duisburg-Essen: ’’Our joint effort within the Consortium will greatly accelerate the development of novel diagnostics as well as therapies for neurodegenerative diseases.’’ Dr. Jan Boesen, CEO IBL International comments: ’’We are pleased that IBL International was chosen as partner in the development and commercialization of the blood-based assay. The development of such assay for early detection is the Holy Grail in Alzheimer’s disease and it will open up the market for routine diagnosis. This agreement fits well with the license agreement with IBL Japan that was signed last month. Under this agreement IBL international will start to manufacture and distribute CE registered Amyloid-ß (1-40) and Amyloid-ß (1-42) ELISAs.’’

 

IBL International GmbH in Hamburg is part of a Dutch holding company and provides one of the widest ranges of immunoassays for special diagnostics to be used in research and routine laboratories. IBL has nearly 30-years of experience and employs 70 people. The company pursues to leverage its assets by securing partnerships in order to place their markers on other technology platforms and for the co-development of companion diagnostics. IBL International has direct sales organizations in Germany, US and the Benelux and an international distribution network on all continents.

 

Neuroallianz Consortium consists of Rheinische Friedrich‐Wilhelms‐Universität Bonn, Universitätsklinikum Bonn, LVR‐Klinikum Essen/Universitätsklinikum Essen, Research Center Jülich GmbH, Fraunhofer Institute SCAI, UCB Pharma GmbH, IBL International, and Life&Brain GmbH.

 

 

 

 

 

For more information please contact:

 

IBL International GmbH:

Jeanine Boesen-de Cock PhD, MBA

Manager Business Development

Phone: +

: Jeanine.Boesen@IBL-International.com

www.IBL-International.com

上一篇:IBL

下一篇:没有了

返回列表>>
在线客服
电话咨询 18018648472
在线客服